{"id":"an2728-ointment","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL2108523","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PDE4 inhibition increases intracellular cAMP levels, which suppresses the production of pro-inflammatory mediators such as TNF-α and IL-2 from T cells and other immune cells. This mechanism reduces skin inflammation and is being developed for topical treatment of inflammatory skin conditions.","oneSentence":"AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:04.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT07367932","phase":"PHASE4","title":"Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Dermatitis, Atopic, Eczema","enrollment":30},{"nctId":"NCT07162896","phase":"PHASE3","title":"Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2026-06","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD)","enrollment":66},{"nctId":"NCT07088276","phase":"NA","title":"Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-08","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT04194814","phase":"PHASE2","title":"Skin bioMARkers for Atopic Eczema Therapy Evaluation","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2020-11-20","conditions":"Atopic Eczema/Dermatitis (Non-Specific)","enrollment":37},{"nctId":"NCT03250663","phase":"PHASE1","title":"Eucrisa for Atopic Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-01","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":28},{"nctId":"NCT05200403","phase":"PHASE4","title":"Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-07-26","conditions":"Atopic Dermatitis","enrollment":72},{"nctId":"NCT04299503","phase":"PHASE2","title":"Topical Crisaborole in Patients with Alopecia Areata","status":"WITHDRAWN","sponsor":"Tufts Medical Center","startDate":"2020-03-06","conditions":"Alopecia Areata","enrollment":""},{"nctId":"NCT03832010","phase":"PHASE4","title":"Steroid-reducing Effects of Crisaborole","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-12-17","conditions":"Atopic Dermatitis, Eczema","enrollment":24},{"nctId":"NCT05298033","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-09-07","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT04800185","phase":"EARLY_PHASE1","title":"Characterizing Skin Microbiome Change in Atopic Dermatitis","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2021-03-23","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema","enrollment":20},{"nctId":"NCT06118047","phase":"PHASE2","title":"Crisaborole Ointment for Skin Toxicity Induced by Cetuximab","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-08-01","conditions":"Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity","enrollment":33},{"nctId":"NCT04040192","phase":"PHASE3","title":"A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-12","conditions":"Atopic Dermatitis","enrollment":620},{"nctId":"NCT03645057","phase":"PHASE3","title":"ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-20","conditions":"Atopic Dermatitis","enrollment":92},{"nctId":"NCT04023084","phase":"PHASE4","title":"Response of Children With Atopic Dermatitis (Eczema) to Eucrisa","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2019-10-03","conditions":"Atopic Dermatitis, Eczema","enrollment":30},{"nctId":"NCT04360187","phase":"PHASE3","title":"Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-27","conditions":"Atopic Dermatitis","enrollment":391},{"nctId":"NCT04091087","phase":"PHASE2","title":"Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-26","conditions":"Stasis Dermatitis","enrollment":66},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT03567980","phase":"PHASE4","title":"A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-01","conditions":"Seborrheic Dermatitis","enrollment":30},{"nctId":"NCT03868098","phase":"PHASE4","title":"Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2019-05-21","conditions":"Dermatitis, Atopic","enrollment":31},{"nctId":"NCT04498403","phase":"PHASE3","title":"A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-09-14","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT04008784","phase":"","title":"Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period","status":"COMPLETED","sponsor":"Clinical Research Center of the Carolinas","startDate":"2019-09-16","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT03351114","phase":"PHASE2","title":"Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-09-01","conditions":"Morphea","enrollment":8},{"nctId":"NCT04214197","phase":"PHASE4","title":"Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT03954158","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-15","conditions":"Atopic Dermatitis","enrollment":81},{"nctId":"NCT03356977","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-16","conditions":"Atopic Dermatitis","enrollment":137},{"nctId":"NCT03233529","phase":"PHASE2","title":"Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-31","conditions":"Dermatitis, Atopic","enrollment":40},{"nctId":"NCT03760042","phase":"PHASE1","title":"Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-14","conditions":"Healthy","enrollment":32},{"nctId":"NCT01258088","phase":"PHASE1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11-30","conditions":"Plaque-type Psoriasis","enrollment":16},{"nctId":"NCT03260595","phase":"PHASE1","title":"A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-13","conditions":"Healthy, Atopic Dermatitis","enrollment":32},{"nctId":"NCT00762658","phase":"PHASE1","title":"A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11-30","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT01301508","phase":"PHASE2","title":"Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Dermatitis, Atopic","enrollment":46},{"nctId":"NCT01652885","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Dermatitis, Atopic","enrollment":23},{"nctId":"NCT01300052","phase":"PHASE2","title":"AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01-26","conditions":"Psoriasis","enrollment":68},{"nctId":"NCT01029405","phase":"PHASE2","title":"Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Psoriasis","enrollment":145},{"nctId":"NCT01602341","phase":"PHASE2","title":"Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Dermatitis, Atopic","enrollment":86},{"nctId":"NCT00755196","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02118766","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":763},{"nctId":"NCT02118792","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":764},{"nctId":"NCT00759161","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Psoriasis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AN2728 Ointment, 5%"],"phase":"phase_2","status":"active","brandName":"AN2728 Ointment","genericName":"AN2728 Ointment","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in immune cells. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}